ReviewBiochimica et biophysica acta2012
Interrogating genomic and epigenomic data to understand prostate cancer.
Review in Biochimica et biophysica acta, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.Oncology reports · 2017Article
- Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG.Translational oncology · 2016Article
- H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.Advances in cancer research · 2016Review
- Review
- Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer.Oncogene · 2015Article
- Autoinhibitory mechanisms of ERG studied by molecular dynamics simulations.AIP advances · 2015Article
- Prostate cancer epigenome.Methods in molecular biology (Clifton, N.J.) · 2015Review
- Article
- Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Review
- Maintaining and reprogramming genomic androgen receptor activity in prostate cancer.Nature reviews. Cancer · 2014Review
- ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients.Korean journal of pathology · 2012Article
- Trends in Gene Expression Profiling for Prostate Cancer Risk Assessment: A Systematic Review.Biomedicine hubReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Major breakthroughs at the beginning of this century in high-throughput technologies have profoundly transformed biological research. Significant knowledge has been gained regarding our biological system and its disease such as malignant transformation. In this review, we summarize leading discoveries in prostate cancer research derived from the use of high-throughput approaches powered by microarrays and massively parallel next-generation sequencing (NGS). These include the seminal discovery of chromosomal translocations such as TMPRSS2-ERG gene fusions as well as the identification of critical oncogenes exemplified by the polycomb group protein EZH2. We then demonstrate the power of interrogating genomic and epigenomic data in understanding the plethora of mechanisms of transcriptional regulation. As an example, we review how androgen receptor (AR) binding events are mediated at multiple levels through protein-DNA interaction, histone and DNA modifications, as well as high-order chromatin structural changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.